Fyodor Urnov is the Director for Technology and Translation at the Innovative Genomics Institute and a Professor of Molecular Therapeutics in the Department of Molecular and Cell Biology at UC Berkeley. He co-developed the toolbox of human genome and epigenome editing, co-named genome editing, and was on the team that advanced all of its first-in-human applications to the clinic. He also led the effort that identified the genome editing target for an approved medicine to treat sickle cell disease and beta-thalassemia. A major goal for the field of genome editing and a key focus of Fyodor's work is expanding access to CRISPR therapies for genetic disease. As part of that effort Fyodor directs the Danaher-IGI Beacon for CRISPR Cures - a first-in-class academia-industry partnership developing and advancing to the clinic scalable CRISPR-based approaches to treat diseases of the immune system. Fyodor also leads cross-functional teams in developing and advancing to the clinic CRISPR-based approaches to treat neurodegenerative, neuroinflammatory, and infectious diseases.